HOMA-IR Explained: An Early Estimate of Insulin Resistance
HOMA-IR combines fasting glucose and fasting insulin into a calculated estimate of insulin resistance. It is particularly useful during the compensated stage of metabolic dysfunction, when the pancreas may be producing additional insulin to keep glucose within the normal range.
The calculation is simple: multiply fasting insulin by fasting glucose and divide by 405 when glucose is reported in mg/dL. A fasting glucose of 95 mg/dL and fasting insulin of 12 µIU/mL produces a HOMA-IR of 2.81.
Higher values generally indicate greater fasting insulin resistance, but there is no universal cutoff. Insulin assays differ, study populations differ, and HOMA-IR changes with age, puberty, pregnancy, ethnicity, body composition, medication use, and pancreatic beta-cell function.
HOMA-IR is best treated as one part of a metabolic assessment rather than a diagnosis. Its value increases when interpreted alongside fasting insulin, A1C, triglycerides, HDL cholesterol, blood pressure, waist circumference, visceral fat, liver health, and change over time. Used carefully, it can reveal metabolic strain that fasting glucose alone may not show.
This article is part of the Metabolic Health and Insulin Resistance Guide, which examines how metabolic dysfunction develops and why early detection matters for long-term health.
HOMA-IR is one of the most commonly discussed calculations in preventive metabolic medicine. It is inexpensive, requires no special procedure, and uses two laboratory values that can be collected during the same fasting blood draw.
Its apparent simplicity can also invite overconfidence. HOMA-IR is an estimate derived from a physiological model. It is not a direct measurement of insulin sensitivity, and the result should not be reduced to a universal pass-or-fail number.
For a comparison with other metabolic tests, see What Blood Tests Detect Insulin Resistance?
What Is HOMA-IR?
HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. The original model was introduced in 1985 as a way to estimate insulin resistance and pancreatic beta-cell function from fasting glucose and insulin concentrations.
The model is based on the feedback relationship between the liver and pancreas during the fasting state:
- The liver releases glucose into circulation.
- The pancreas releases insulin in response.
- Insulin restrains hepatic glucose production.
- Fasting glucose and insulin settle into a balance reflecting both insulin sensitivity and pancreatic compensation.
When the liver and other tissues become less responsive to insulin, the pancreas may produce more insulin to maintain fasting glucose. HOMA-IR uses the relationship between those two values to estimate the degree of resistance.
Because it relies on fasting physiology, HOMA-IR is particularly influenced by hepatic insulin resistance. It does not fully capture what happens in skeletal muscle after a meal.
How Is HOMA-IR Calculated?
The correct formula depends on the units used for glucose.
When fasting glucose is reported in mg/dL:
HOMA-IR = fasting insulin (µIU/mL) × fasting glucose (mg/dL) ÷ 405
When fasting glucose is reported in mmol/L:
HOMA-IR = fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5
Using 405 with a glucose result reported in mmol/L, or 22.5 with a glucose result reported in mg/dL, will produce an incorrect answer.
Some laboratories calculate HOMA-IR automatically. When they do not, the formula can be applied manually as long as the blood draw was performed under appropriate fasting conditions and the units are correct.
A Worked HOMA-IR Example
Consider the following fasting results:
- Fasting glucose: 95 mg/dL
- Fasting insulin: 12 µIU/mL
12 × 95 ÷ 405 = 2.81
The fasting glucose is below the prediabetes threshold of 100 mg/dL. Looking only at glucose could therefore appear reassuring.
The HOMA-IR result shows that maintaining this glucose required a fasting insulin of 12. That may indicate compensatory hyperinsulinemia and reduced fasting insulin sensitivity, depending on the laboratory, population, and broader clinical picture.
The calculation does not prove that the person has a disease. It reveals information that the glucose value cannot provide by itself.
How Should a HOMA-IR Result Be Interpreted?
HOMA-IR is a continuous marker. Metabolic risk does not suddenly appear when the result crosses one exact decimal point.
In a large German population study, median HOMA-IR values were:
- 1.09 in a stringently selected metabolically healthy reference group
- 1.54 among adults without diabetes
- 2.00 among adults with prediabetes
- 4.00 among adults with diabetes
The 97.5th percentile in the stringently healthy reference group was 2.35. The same study found systematic differences when the same samples were tested with three different insulin assays.
Those findings are useful context, not universal clinical thresholds. Other studies have proposed cutoffs below 2, around 2.5, above 3, or even higher, depending on the population and outcome being studied.
A HOMA-IR result is most informative when compared with:
- the laboratory’s insulin assay and reference information
- other metabolic markers
- body composition and waist circumference
- the person’s age and clinical circumstances
- previous results obtained under comparable conditions
Serial measurements from the same laboratory may be more useful than comparing one result with a cutoff taken from an unrelated population.
Why Is There No Universal HOMA-IR Cutoff?
Several factors prevent HOMA-IR from having a single diagnostic threshold.
Insulin Assays Are Not Fully Standardized
Different laboratory methods can produce different insulin results from the same sample. Because insulin is part of the HOMA-IR equation, those differences pass directly into the calculated score.
Populations Differ
Published reference ranges vary by age, sex, pubertal status, pregnancy, ethnicity, body composition, and prevalence of metabolic disease.
Studies Use Different Reference Standards
Some studies choose a cutoff based on metabolic syndrome. Others compare HOMA-IR with a glucose clamp, future diabetes risk, fatty liver disease, or a percentile within a supposedly healthy population.
Beta-Cell Function Changes the Result
HOMA-IR assumes that the pancreas can still respond to insulin resistance by producing more insulin. If beta-cell function declines, insulin may no longer remain elevated. Glucose can worsen while HOMA-IR becomes less representative of the underlying resistance.
For these reasons, HOMA-IR should be interpreted as an estimate along a continuum, not a universally standardized diagnosis.
HOMA-IR, HOMA1, and HOMA2
The familiar equation using 405 or 22.5 is commonly called HOMA1-IR. It treats the glucose-insulin relationship as relatively simple.
HOMA2 is a later computer-based model that accounts for more of the nonlinear relationship between glucose and insulin. Depending on the calculator and clinical setting, HOMA2 can use insulin or C-peptide and may estimate:
- HOMA2-IR
- insulin sensitivity
- beta-cell function
HOMA1 and HOMA2 values are not interchangeable. A number produced by the simple formula should not be compared directly with a cutoff developed for HOMA2.
For ordinary clinical discussion, “HOMA-IR” usually refers to the original equation. Research papers should be checked carefully to determine which model was used.
What Does HOMA-IR Actually Measure?
HOMA-IR estimates the insulin resistance reflected in the fasting balance between glucose production and insulin secretion.
Because the liver controls much of fasting glucose production, HOMA-IR is often considered most reflective of hepatic insulin resistance. Skeletal muscle insulin resistance may become more apparent after a glucose or carbohydrate challenge.
This means a person can have a relatively reassuring fasting HOMA-IR while showing an abnormal post-meal glucose or insulin response.
Depending on the clinical question, additional tools may include:
- an oral glucose-tolerance test
- insulin measurements during a glucose challenge
- continuous glucose monitoring
- triglyceride-based metabolic markers
- body-composition assessment
No one of these replaces the others. They examine different parts of metabolic physiology.
Is HOMA-IR Better Than Fasting Glucose?
HOMA-IR and fasting glucose answer different questions.
Fasting glucose measures the concentration of glucose in the blood. It is part of accepted criteria for diagnosing prediabetes and diabetes.
HOMA-IR estimates how fasting glucose relates to the insulin concentration required to maintain it. It may reveal compensatory hyperinsulinemia while glucose remains normal.
HOMA-IR can therefore provide earlier information in some people, but it is not categorically “better.” It has greater assay variability, lacks a universal cutoff, and becomes less reliable when beta-cell function is impaired.
The most informative approach is generally to evaluate glucose and insulin together rather than choosing one and ignoring the other.
When Can HOMA-IR Be Misleading?
HOMA-IR is less reliable or more difficult to interpret under several circumstances:
- the blood sample was not collected after an appropriate fast
- the person uses injected insulin
- pancreatic beta-cell function is substantially impaired
- glucose or insulin values are far outside the range for which the model performs well
- acute illness, severe stress, or recent glucocorticoid exposure affects the result
- pregnancy or puberty changes normal insulin physiology
- the person recently made a major dietary change
- results from different laboratories or insulin assays are compared directly
HOMA-IR is also not designed to diagnose type 1 diabetes or distinguish among the different causes of hyperglycemia.
A worsening glucose value with a falling insulin concentration should not automatically be interpreted as improving insulin sensitivity. It may reflect declining pancreatic insulin production.
HOMA-IR, Visceral Fat, and Fatty Liver
Higher HOMA-IR commonly occurs alongside increased visceral fat, elevated triglycerides, fatty liver disease, and other features of metabolic syndrome.
Visceral adipose tissue releases fatty acids and signaling molecules that can interfere with insulin action in the liver and skeletal muscle. Fat accumulation within the liver can further impair hepatic insulin sensitivity.
Body weight alone does not show where fat is stored or how much lean mass a person carries. Someone with a normal BMI can still have excess visceral fat or low muscle mass.
A DEXA body-composition scan can add measurements of regional fat, lean mass, and estimated visceral adipose tissue.
HOMA-IR and Cardiovascular Risk
Insulin resistance frequently occurs with higher triglycerides, lower HDL cholesterol, increased remnant lipoproteins, hypertension, visceral fat, fatty liver disease, and chronic low-grade inflammation.
These abnormalities can increase cardiovascular risk even before diabetes develops.
HOMA-IR is not a direct measurement of arterial plaque and should not replace apoB, blood pressure assessment, smoking history, family history, or appropriate cardiovascular imaging. It contributes metabolic context to a broader preventive-cardiology assessment.
See the Preventive Cardiology and Heart Disease Prevention Guide.
Putting HOMA-IR Into Clinical Context
A HOMA-IR result should be reviewed alongside other relevant findings:
- fasting glucose and fasting insulin
- hemoglobin A1C
- triglycerides and HDL cholesterol
- apoB
- blood pressure
- waist circumference
- visceral fat and lean mass
- liver enzymes and assessment for fatty liver when indicated
- sleep, physical activity, nutrition, medications, and family history
When the pattern suggests insulin resistance, improving the underlying physiology may involve resistance training, aerobic activity, increased muscle mass, reduced visceral fat, improved sleep, a plant- and protein-forward Mediterranean dietary pattern, and medication when clinically appropriate.
The result should then be repeated under comparable conditions to determine whether the intervention is changing the metabolic pattern.
The HormoneSynergy® View
HOMA-IR is useful because it asks a better question than fasting glucose alone: how much insulin is required to maintain that glucose?
It remains an estimate. It is sensitive to laboratory methods, pancreatic function, fasting conditions, and the population used for comparison.
The right way to use HOMA-IR is neither to dismiss it nor to turn one decimal point into a diagnosis. It belongs within a larger metabolic assessment and is particularly helpful for following direction over time.
When the score, body composition, lipids, blood pressure, and clinical history point in the same direction, the signal becomes much more meaningful.
Frequently Asked Questions
What does HOMA-IR measure?
HOMA-IR estimates insulin resistance from the fasting relationship between glucose and insulin. It is particularly influenced by fasting or hepatic insulin resistance.
How do I calculate HOMA-IR?
When glucose is measured in mg/dL, multiply fasting insulin by fasting glucose and divide by 405. When glucose is measured in mmol/L, multiply fasting insulin by fasting glucose and divide by 22.5.
What is a normal HOMA-IR?
There is no universal normal value. Results depend on the insulin assay, population, age, body composition, and clinical context. In one large adult cohort, the median was 1.09 in a stringently healthy reference group and the 97.5th percentile was 2.35.
Is a HOMA-IR above 2 insulin resistance?
Possibly, but not automatically. Some studies use cutoffs around 2 or 2.5, while others use higher or lower thresholds. The result must be interpreted with the laboratory method and the person’s broader metabolic pattern.
Can HOMA-IR be elevated when glucose is normal?
Yes. This can occur when the pancreas produces additional insulin to maintain normal fasting glucose.
Can HOMA-IR diagnose diabetes?
No. Diabetes is diagnosed using recognized glucose or A1C criteria. HOMA-IR estimates insulin resistance but is not a diagnostic criterion for diabetes.
Can HOMA-IR improve?
Yes. Improved insulin sensitivity from exercise, increased muscle mass, reduced visceral fat, better sleep, dietary changes, and appropriate medical treatment may lower fasting insulin and HOMA-IR.
Selected References
- Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in humans.
- Gastaldelli A, et al. Measuring and estimating insulin resistance in clinical and research settings.
- Matli B, et al. Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals.
- Arellano-Ruiz P, et al. HOMA-IR cutoff points related to metabolic syndrome: a systematic review and meta-analysis.
Medical disclaimer: This article is for educational purposes and is not a substitute for individualized medical diagnosis or treatment. Fasting insulin and HOMA-IR should be interpreted by a qualified healthcare professional in the context of laboratory methods, medications, medical history, body composition, glucose regulation, and other metabolic findings.
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →